311 results about "Toxic reaction" patented technology

The invention belongs to the technical field of traditional Chinese medicine preparation method, and provides a preparation method of a traditional Chinese medicine used for treating gastritis caused by insufficiency of spleen-yang. According to prior arts, gastritis caused by insufficiency of spleen-yang is commonly treated by using omeprazole, which causes adverse reactions. The technical scheme of the invention is that: traditional Chinese medicines of ginseng, human milk, common jujube, common yam rhizome, wheat, different leaves pseudostellaria root tuber, balck-bone silky fowl, wild cabbage, dried longan pulp, largehead atractylodes rhizome, radix paeoniae alba, American ginseng, ligusticum, lotus seed, pilose asiabell root, sharpleaf galangal fruit, mongolian milkvetch root, Siberian solomonseal rhizome, nonglutinous rice, edible bird nest, dried ginger, bayberry, garden radish seed, carica papaya, roof iris rhizome, carrot, buckwheat, medicated leaven, cydonia oblonga mill, cerealose, honey, and licorice are soaked in water, and are decocted by using a mild fire; the obtained solution is filtered, a slag is removed, and the obtained medicine liquid is the traditional Chinese medicine used for treating gastritis caused by insufficiency of spleen-yang. The method is advantaged in that: the preparation method is simple; toxic and side-effects of the traditional Chinese medicine liquid are low; a treatment course is short; and a recovery rate is high. According to the invention, a good effect can be obtained with the cooperation of monarch and minister medicines. A traditional Chinese medicine preparation is adopted, such that adverse reactions, allergic reactions and toxic reactions caused by western medicines are avoided.

The invention relates to the field of chemical and biological sciences, in particular to LQC-X structural formula I, and synthesis and application of intermediate of LQC-X, wherein a maximum dosage of LQC-X6 given to an mouse is 2000 mg/kg once in one day; the mouse is continuously observed for 7 days; no toxic reaction appears, and the medicine is proven to have quite high safety; and it is proved through pharmacodynamics experiments that LQC-X compounds have obvious anti-hepatitis B virus action and liver protecting and transaminase lowering action. The compounds can be used for preparing medicines for preventing and treating diseases of hepatitis B, chronic liver cirrhosis and the like. The structural formula I of LQC-X is shown in the description.

The present invention relates to an anticancer medicine composition and belongs to the field of medicine technology. The anticancer medicine composition contains topomerase inhibitor and medicinal supplementary material. The topomerase inhibitorcan inhibit intracellular DNA repair function and reduce the tolerance one tumor cell on anticancer nitrosourea medicine; and the medicine supplementary material is mainly degradable biocompatible polymer. During the degrading and absorption process of the supplementary material, the anticancer medicine is released slowly to the tumor part, and this can lower the systemic toxic reaction while maintaining local effective medicine concentration. The anticancer medicine composition contains also anticancer nitrosourea medicine, and is set to the tumor part locally to enhance the treatment effect.

The invention discloses an application of in-situ crosslinking hydrogel in preparing artificial vitreous bodies, which is characterized in that the in-situ crosslinking hydrogel is prepared by in-situ crosslinking after mixing a four-arm-end mercapto polyethylene glycol solution shown in the formula (I) and a polymer solution shown in the formula (II); wherein m in the formula (I) is an integer larger than 1, and n in the formula (II) is an integer larger than 1; and the two solutions are filled in eyes without vitreous bodies after mixing and can effectively form gel. A cell experiment and an animal in vivo experiment prove that the in-situ crosslinking hydrogel does not cause obvious inflammatory reaction and intraocular organ toxic reaction and can be used as the artificial vitreous bodies.

The invention provides an artificial liver tissue and a preparation method thereof. The artificial liver tissue comprises a lower chip, a first microporous membrane, a middle chip, a second microporous membrane and an upper chip from the top to the bottom in sequence in a laminated manner. Three layers of cavities of a lower cavity, a middle cavity and an upper cavity are formed in the lower chip, middle chip and upper chip respectively. Three cavities are all grouted with culture solution containing growth factor, extracellular matrix containing hepatic parenchymal cells and suspension liquid containing endothelial cells. Adjacent cavities are separated by the microporous membrane. The microporous membrane can separate the matrix flow outside of the cell, and cause no influence to the cell migration. The culture solution and is fed through an inlet and an outlet of the upper cavity and lower cavity. Under the guidance of the growth factor, endothelial cells pass through the extracellular matrix of the middle cavity to form a lumen, and form the artificial liver tissue containing capillaries. The artificial liver tissue can simulate the human body liver tissue in a good way, and simulate the intrahepatic capillary functions of mass transfer, selective permeability, toxic reaction and the like.

The present invention is solid tumor treating medicine composition and belongs to the field of medicine technology. The medicine composition contains melphalan in effective anticancer amount and medicinal supplementary material. The medicinal supplementary material is mainly biocompatible, degradable and absorbable polymer, and during the degradation and absorption of the polymer, melphalan is released slowly to local tumor part to lower the systemic toxic reaction and to maintain local medicine concentration. The present invention has enhanced treating effect. The solid tumor includes cerebral tumor, liver cancer, lung cancer, esophagus cancer, gastric cancer, etc.

The invention relates to a tumor tissue tumor infiltrating lymphocyte (TIL) cell preparation method and a dedicated culture medium. The method comprises the following steps of tumor surrounding tissue obtaining, cell digestion, cell primary culture, cell subculture and cell collection, wherein a primary culture medium is based on a RPMI 1640 culture medium and prepared from the following concentration ingredients of 10% volume of human-derived serum, 20 to 45ng/ml of basic fibroblast growth factor (bFGF), 1 to 5mg/ml of riboflavin, 70 to 90ng/ml of cortisol, 10 to 25mg/ml of sodium dihydrogen phosphate monohydrate, 47 to 62ng/ml of recombinant human leukaemia inhibitory factor (LIF) and 500 to 800U/ml of IL-2; a subculture medium is based on the RPMI 1640 culture medium and prepared from the following concentration ingredients of 10% volume of the human-derived serum, 20 to 40mmol/L of HEPES, 1000 to 2000U/ml of the IL-2, 0.03 to 0.07mmol/L of beta-mercaptoethanol and 5 to 15ng/ml of sodium phosphate. According to the preparation method, an existing culture medium is improved, different culture mediums are utilized to culture the TIL cells in pertinence, TIL cell expansion capacity is improved, meanwhile a culture period is reduced, a culture complexity degree is reduced, a use amount of the IL-2 is reduced, and toxic reaction is reduced.

The slow released anticancer injection containing methotrexate and its synergist consists of slow released microballoon and solvent. The slow released microballoon includes effective anticancer component and slow releasing supplementary material, and the solvent is common solvent or special solvent containing suspending agent. The effective anticancer component is methotrexate synergist or the composition of methotrexate and its synergist; the methotrexate synergist is selected from phosphorinositide 3-kinase (PI3K) inhibitor, pyrimidine analogue and DNA repair enzyme inhibitor; the slow releasing supplementary material is PLA, PLGA, EVAc, etc or their composition; and the suspending agent is sodium carboxymethyl cellulose, etc. The slow released microballoon may be also prepared into slow released implantation preparation. Implanting or injecting the slow released preparation to local tumor part can lower the systematic toxic reaction of the medicine and raise the medicine concentration of local tumor part selectively to raise the treating effect.

An anticancer pharmaceutical composition composed of pharmaceutic adjuvant and anti-metabolism medicine is disclosed. Wherein, the anti-metabolism medicine can effectively destroy DNA and/or protein synthesis and repairing function inside the tumor cell so as to inhibit the tumor cell growth, while the pharmaceutic adjuvant can mainly be biological compatible, degradable and absorbable macromolecule polymer, which can make the anti-metabolism drug to release slowly in the local tumor region in the degradation and absorption process, therefore it can both decrease considerably the whole body toxic reaction and sustain the local tumor effective drug level.

The invention relates to a medicine with effective component of plant nodicorn, which is characterized in that: said effective components can be polyphenol and monomer caffeic acid 3, 4- dihydroxyphenylglycol; the monomer caffeic acid 3, 4- dihydroxyphenylglycol is extracted and purified from nodicorn and other plants; the preparation of polyphenol and the extraction of monomer caffeic acid 3, 4- dihydroxyphenylglycol comprise: refluxing and extracting alcohols in different densities, boiling, extracting butanol, macroreticular resinous adsorbent chromatography and positive and passive silicon gel chromatography. The invention can treat cancer, attenuate, and treat general bacteria infection.

An anti-cancer composition comprises anti-cancer effective component selected from tyrosine kinase inhibitor and/or bendamustine and slow releasing adjuvant, and can be prepared into slow releasing injection and slow releasing implantable agent. The slow releasing injection also comprises special dissolvant containing suspending agent. The Suspending agent has a viscocity of 100cp-3000cp (at 20deg.C-30deg.C) and is selected from sodium carboxymethylcellulose, and so on. the slow releasing adjuvant is selected from p(LAEG-EOP), p(DAPG-EOP), p(BHET-EOP/TC), p(BHET-EOP/TC), p(BHDPT-EOP/TC), p( BHDPT-EOP/TC), p(CHDM-HOP) or p(CHDM-EOP.Slow releasing injection and implantable agent can keep high medicinal concentration in tumour part through slow releasing for over 60 days after being injected or implanted in or around tumour. The anticancer composition may also be prepared into sustained-release implant. It can reduce systemic toxic reaction of anticancer drugs, and also selectively improve the therapeutic effect of non-operative therapy such as chemotherapy.

The invention relates to the technical field of medicaments, and particularly relates to a composition for teriparatide injection, and a preparation method and preparation thereof. The composition for teriparatide injection comprises teriparatide, a freezing and drying protecting agent and a pH regulator, wherein the mass ratio of the teriparatide to the freezing and drying protecting agent is 1:(10-100000). The composition for teriparatide injection is simple in formula; the freezing and drying protecting agent ensures that the teriparatide is not degraded in preparation and preservation processes; and the pH regulator is used for regulating the pH value in a preparation process and regulating the pH value after the composition for teriparatide injection is redissolved, so as to maintain the stability of the teriparatide. The used auxiliary materials are safe, and do not cause toxic reaction. Therefore, the composition for teriparatide injection provided by the invention is good in stability, simple and reasonable in formula, and good in redissolving performance, and can be prepared into powder-injection or injection and is needless to be prepared into a pen-type injector. Thus, the production technology is simple.

The invention discloses a method for quickly preparing polyethylene glycol regulated and controlled nano hydroxyapatite and belongs to the field of preparation of biomedical materials. The method comprises the following process steps: preparing a calcium salt solution and a phosphate solution respectively, and mixing the calcium salt solution and the phosphate solution with equal volumes; adjusting the pH value of a reaction system by using ammonia water while stirring; adding polyethylene glycol, and heating the reaction system; and performing centrifuging and washing after reaction, and collecting granular deposits to obtain nano hydroxyapatite granular powder. The method disclosed by the invention is simple in preparation process, strong in laboratory operability, low in production cost and high in product yield and is suitable for laboratory research application and industrial production; and moreover, the prepared rod-shaped nano hydroxyapatite has good dispersity, does not have toxic reaction to normal cells and cancer cells, and has a huge application potential in the fields of biomedicine and biological materials such as drug controlled-release vectors, gene therapy vectors and the like.

The invention discloses an aryl propionic acid derivative composition and a pharmaceutical purpose. Alcohol metabolites of Loxoprofen having highest activity in metabolism is used as a nuclear parent to produce a series of derivatives of phosphate, sulphonate, carbonic ester, and amino-acid ester. The derivatives are used to enhance pesticide effect of anti-inflammatory and analgesic effects, and reduce toxic reaction, and have good pharmacokinetic property. And at the same time, the stimulation of the medicine on the gastrointestinal tract, and medication compliance of patients is improved, and therefore the aryl propionic acid derivative composition is the non-steroidal anti-inflammatory drugs having potentials.

The invention relates to a Chinese medicinal compound preparation for resisting virus and treating flu and cold. The preparation consists of the following raw materials by weight: 300 to 600g of honeysuckle, 200 to 400g of indigowoad leaf, 200 to 400g of weeping forsythia capsule, 200 to 400g of Chinese thorowax root, 200 to 400g of baical skullcap root, 200 to 400g of platycodon grandiflorum, and 1 to 10g of menthol. Pharmacodynamic tests prove that honeysuckle and Chinese thorowax root anti-flu capsules have the effects of reducing fever, diminishing inflammation and relieving cough, wherein the effect of reducing fever is more remarkable. Acute toxicity tests prove that: the safe dosage of the Chinese medicinal composition is equivalent to 371.2 times that of maximum clinical dosage of a human. Long-term toxicity test researching results prove that: remarkable toxic changes or delayed toxicity reactions caused by medicament are not found. The Chinese medicinal compound preparation has the functions of clearing heat and removing toxicity, coursing wind and dissipating heat, and ventilating lung and relieving cough, and has the advantages of convenient use, controllable quality, definite drug effect and safety and reliability.

Disclosed is a preparation process of ossotide injection (gutai), belonging to the medical technical field. To solve the defects of the existing ossotide injection (gunning), the novel ossotide injection (gutai) preparation process is produced by the change of the existing ossotide injection (gunning) process. In the invention, four bones of a pig is picked up, degreased, condensed, and then precipitated and condensed, and then after acid precipitation and alkaline precipitation, the heated liquid is cooled to be in the room temperature and then is placed in a refrigerator; the liquid is taken out from the refrigerator and acidic protein is removed from the liquid is filtrated and hyperfiltrated to become the ossotide stock solution which is mixed with water, filtrated, potted and sterilized, thus the ossotide injection (gutai) is prepared well. The invention removes sensitizer and toxicant, largely reduces toxic reaction for the ossotide injection (gutai), and makes medicine for intravenous injection possibly used.

The invention relates to Toltrazuril injection and a preparation method thereof. Every 100ml of Toltrazuril injection contains the following raw materials: 1-2g of Toltrazuril, 2-5g of hydrogenated castor oil, 9-25ml of N-methyl-pyrrolidone, 0.5-1ml of 1,2-propylene glycol and 5% of polyvinylpyrrolidone aqueous solution which complements the solution to be 100ml. By means of the addition of formaldehyde carboxy glycerin or 1,2-propylene glycol in the Toltrazuril injection, the medicine can be slowly released to the attack part of the disease during degradation and absorption, so that toxic reaction of the whole body is obviously reduced, and simultaneously effective medicine concentration at the local position can be maintained. The Toltrazuril injection prepared by the method is good in injection performance, not apt to block, strong in stability, not apt to layer, small in toxic reaction of the whole body due to partial injection, and capable of selectively improving medicine concentration of the attacked part and strengthening curing effect. The Toltrazuril injection is convenient to use compared with an orally-taken preparation and good in effect when used for preventing and curing coccidiosis of animals such as chickens, sheep and rabbits.